Document is current
Any future updates will be listed below
-
Authors
Taves, Sarah
Sun, Junjiang
Livingston, Eric W.
Chen, Xin
Amiaud, Jerome
Brion, Regis
Hannah, William B.
Bateman, Ted A.
Heymann, Dominique
Monahan, Paul E.
-
Funding
Funding for this research was provided by:
Novo Nordisk
During the conduct of these studies Sarah Taves was an employee of Novo Nordisk via the STAR Fellowship mechanism.
- License Information
-
More Information
Article History
Received: 30 October 2018
Accepted: 19 September 2019
First Online: 8 October 2019
Competing Interests
: Prof. P.E. Monahan during the conduct of these studies received research support through the University of North Carolina from Baxter Healthcare, Asklepios BioPharmaceutical and Novo Nordisk. He has received research support in the past from Baxter Healthcare, Novo Nordisk, and Pfizer. He holds patents licensed to Asklepios, for which he receives royalties. He has received payment for consultation, services, and for speaking for Asklepios, Chatham LLC, Baxter Healthcare and Pfizer and has additionally consulted for Bayer, Novo Nordisk, and Biogen. Following the completion of these studies but during a portion of the time of manuscript preparation he was an employee of Baxalta (now a part of Shire). He is now an employee of Spark Therapeutics.” Dr T.A. Bateman has received compensation for consulting and speaker work for Baxter Health Care Corporation and research support from Novo Nordisk. Prof. D. Heymann has received research support from Baxter/Baxalta (now a part of Shire). Dr Sarah Taves was an employee of Novo Nordisk (during the conduct of these studies) via the STAR Fellowship mechanism. J. Sun, EW Livingston, X Chen, J Amiaud, R Brion, WB Hannah have no relevant disclosures or conflicts of interest to declare.
